|13th December 2019||Cary Sucoff||50,000||Open or private purchase||$0.39||$19,500.00|
|13th December 2019||Michael Messinger||5,000||Open or private purchase||$0.37||$1,850.00|
|13th December 2019||David N. Low||300,000||Open or private purchase||$0.43||$129,000.00|
|20th June 2019||Cary Sucoff||25,000||Grant/award etc.||$0.15||$3,750.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
ContraFect Corp. is a clinical stage biotechnology company. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections.